Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer |
| |
| Authors: | Masakatsu Nakamura Toshimi Otsuka Ranji Hayashi Tomoe Horita Masafumi Ota Naoko Sakurai Hikaru Takano Tasuku Hayashi Motona Kumagai Sohsuke Yamada Tomiyasu Arisawa |
| |
| Affiliation: | 1.Department of Gastroenterology, Kanazawa Medical University, Japan;2.Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan |
| |
| Abstract: | We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged. |
| |
| Keywords: | immune-related hepatitis durvalumab non-small cell lung cancer |
|
|
